Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin in Type 2 Diabetes
NCT00813995Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2008
- Primary completion
- Aug 2010
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin Arm with Placebo Arm (2 arms). Primary endpoint: Change From Baseline in Hemoglobin A1c (A1C) at Week 24. Started Dec 2008; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00813995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00813995.